Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to 0.65.

  • Immucell's Equity Ratio rose 967.08% to 0.65 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.65, marking a year-over-year increase of 967.08%. This contributed to the annual value of 0.61 for FY2024, which is 694.82% up from last year.
  • As of Q3 2025, Immucell's Equity Ratio stood at 0.65, which was up 967.08% from 0.64 recorded in Q2 2025.
  • Immucell's 5-year Equity Ratio high stood at 0.74 for Q2 2021, and its period low was 0.56 during Q2 2024.
  • For the 5-year period, Immucell's Equity Ratio averaged around 0.65, with its median value being 0.65 (2025).
  • Per our database at Business Quant, Immucell's Equity Ratio plummeted by 1575.53% in 2023 and then surged by 1407.61% in 2025.
  • Quarter analysis of 5 years shows Immucell's Equity Ratio stood at 0.73 in 2021, then fell by 7.56% to 0.68 in 2022, then decreased by 15.76% to 0.57 in 2023, then rose by 6.95% to 0.61 in 2024, then increased by 6.8% to 0.65 in 2025.
  • Its Equity Ratio was 0.65 in Q3 2025, compared to 0.64 in Q2 2025 and 0.64 in Q1 2025.